- Home
- UROY vs RCKT Comparison
UROY vs RCKT Comparison
Compare UROY & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | UROY | RCKT |
|---|---|---|
| Founded | 2017 | 1999 |
| Country | Canada | United States |
| Employees | N/A | 202 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 601.8M | 534.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | UROY | RCKT |
|---|---|---|
| Price | $3.34 | $3.77 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 14 |
| Target Price | $4.50 | ★ $29.65 |
| AVG Volume (30 Days) | 2.3M | ★ 3.2M |
| Earning Date | 03-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $275.63 | N/A |
| Revenue Next Year | N/A | $51.17 |
| P/E Ratio | $1,584.46 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.43 | $2.19 |
| 52 Week High | $5.52 | $8.26 |
Technical Indicators
Market Signals| Indicator | UROY | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 36.30 | 39.55 |
| Support Level | $3.13 | $2.91 |
| Resistance Level | $4.03 | $4.08 |
| Average True Range (ATR) | 0.19 | 0.38 |
| MACD | -0.02 | -0.11 |
| Stochastic Oscillator | 15.29 | 4.70 |
Price Performance
Historical ComparisonAbout UROY Uranium Royalty Corp.
Uranium Royalty Corp is focused on gaining exposure to uranium prices by making investments in uranium interests, including royalties, streams, debt and equity investments in uranium companies, and through holdings of physical uranium. The company operates in a single segment that is acquiring and assembling a portfolio of royalties, investing in companies with exposure to uranium and physical uranium. The Company also engages in the purchase and sale of physical uranium.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.